Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
Open Access
- 9 August 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 7 (1), 12498
- https://doi.org/10.1038/ncomms12498
Abstract
Resistance to oestrogen-deprivation therapy is common in oestrogen-receptor-positive (ER+) breast cancer. To better understand the contributions of tumour heterogeneity and evolution to resistance, here we perform comprehensive genomic characterization of 22 primary tumours sampled before and after 4 months of neoadjuvant aromatase inhibitor (NAI) treatment. Comparing whole-genome sequencing of tumour/normal pairs from the two time points, with coincident tumour RNA sequencing, reveals widespread spatial and temporal heterogeneity, with marked remodelling of the clonal landscape in response to NAI. Two cases have genomic evidence of two independent tumours, most obviously an ER− ‘collision tumour’, which was only detected after NAI treatment of baseline ER+ disease. Many mutations are newly detected or enriched post treatment, including two ligand-binding domain mutations in ESR1. The observed clonal complexity of the ER+ breast cancer genome suggests that precision medicine approaches based on genomic analysis of a single specimen are likely insufficient to capture all clinically significant information.This publication has 34 references indexed in Scilit:
- Genome Modeling System: A Knowledge Management Platform for GenomicsPLoS Computational Biology, 2015
- Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingScience, 2014
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancerNature Genetics, 2013
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- The Life History of 21 Breast CancersCell, 2012
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Predicting response and resistance to endocrine therapyCancer, 2007
- Molecular response to aromatase inhibitor treatment in primary breast cancerBreast Cancer Research, 2007
- Breast Cancer–Amplified Sequence 3, a Target of Metastasis-Associated Protein 1, Contributes to Tamoxifen Resistance in Premenopausal Patients with Breast CancerCell Cycle, 2006